SCHEDULE: Gagnon Entities Boost Stake in Treace Medical to 9.6%

Neil Gagnon and affiliated entities, Gagnon Securities LLC and Gagnon Advisors, LLC, reported a combined beneficial ownership of 9.6% in Treace Medical Concepts, Inc. as of December 31, 2025.

Summary

• Neil Gagnon, along with Gagnon Securities LLC and Gagnon Advisors, LLC, collectively reported beneficial ownership of 6,142,107 shares of Treace Medical Concepts, Inc. common stock.
• This represents 9.6% of the company's outstanding common stock, based on 63,718,073 shares outstanding as of October 31, 2025.
• Gagnon Securities LLC beneficially owns 3,928,051 shares, which is 6.2% of the class, primarily with shared voting and dispositive power.
• Gagnon Advisors, LLC beneficially owns 1,534,034 shares, representing 2.4% of the class, with shared voting and dispositive power.
• Neil Gagnon holds sole voting and dispositive power over 420,406 shares and shared voting and dispositive power over a larger portion through his roles at the affiliated entities.
• The reporting persons certified that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable investment firm and its principal often indicates a belief in the company's value and future prospects, even if it's a passive investment.

Positives

• Significant beneficial ownership by an institutional investor and its principal, indicating confidence in Treace Medical Concepts, Inc.
• Neil Gagnon's aggregate ownership of 9.6% suggests a strong conviction in the company's long-term prospects.

Negatives

• NA

Risks

• The filing itself does not detail specific risks for Treace Medical Concepts, Inc. It is a disclosure of ownership.
• Potential for future activist involvement if the 'changing or influencing control' certification is later challenged or if the investor decides to pursue such actions (though currently disclaimed, except for Rule 14a-11 nominations).

Future Outlook

NA

Management Comments

• I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that significant beneficial ownership by an investment firm like Gagnon Securities and its principal, Neil Gagnon, often signals a vote of confidence in the company's strategy and market position within the medical device sector. Such disclosures can attract further institutional interest, potentially influencing market perception and liquidity for Treace Medical Concepts, Inc.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence and attracting other investors. It could also lead to increased scrutiny or potential for future engagement if the stake grows or the investor becomes more active.
• Management: Awareness of a significant institutional holder may influence strategic decisions or communication with the investment community.

Key Dates

Recommendation

The filing indicates a significant and continued institutional interest in Treace Medical Concepts, Inc. by Neil Gagnon and his affiliated entities, with a combined 9.6% stake. While this is a positive signal of investor confidence, a Schedule 13G is a passive filing and does not provide new operational or financial data to warrant a 'buy' recommendation. It primarily confirms a substantial existing position. Investors should 'hold' and monitor future developments, including any changes in this ownership or the company's performance, to assess further action.

Keywords

Treace Medical Concepts, TRAC, Gagnon Securities, Gagnon Advisors, Neil Gagnon, Beneficial Ownership, SEC Filing, Schedule 13G, Institutional Investor, Common Stock